Robert B. Den
Advanced in Retinoblastoma

Dr. Robert B. Den

Radiation Oncology | Oncology
Jefferson Health
Radiation Oncology At Thomas Jefferson University Hospital
111 South 11th Street, Suite G-301, 
Philadelphia, PA 
Accepting New Patients
Advanced in Retinoblastoma
Jefferson Health
Radiation Oncology At Thomas Jefferson University Hospital
111 South 11th Street, Suite G-301, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Den is an Oncologist and a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Den is rated as an Advanced provider by MediFind in the treatment of Retinoblastoma. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, Retinoblastoma, and Prostatectomy. Dr. Den is currently accepting new patients.

His clinical research consists of co-authoring 177 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles and participated in 1 clinical trial in the study of Retinoblastoma.

Graduate Institution
Harvard Medical School
Residency
Thomas Jefferson University Hospitals
Specialties
Radiation Oncology
Oncology
Licenses
Internal Medicine in MA
Board Certifications
Radiology
Radiation Oncology
Hospital Affiliations
Thomas Jefferson University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
View 4 Less Insurance Carriers -

Locations

Radiation Oncology at Thomas Jefferson University Hospital
111 South 11th Street, Suite G-301, Philadelphia, PA 19107

Additional Areas of Focus

Dr. Den has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Cervical Cancer
Endometrial Cancer
Bladder Cancer
Ovarian Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 01, 2025
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate Cancer
Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Drug, Radiation
Study Drugs: Enzalutamide, Goserelin Acetate, Leuprolide Acetate
Study Phase: Phase 1
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
Enrollment Status: Active_not_recruiting
Publish Date: October 28, 2025
Intervention Type: Radiation
Study Phase: Phase 3
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)
Enrollment Status: Active_not_recruiting
Publish Date: October 03, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Radiation
Study Phase: Phase 3
A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients
A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients
Enrollment Status: Completed
Publish Date: June 06, 2025
Intervention Type: Behavioral, Radiation, Procedure, Other
Study Phase: Not Applicable
ARN-509+Abiraterone Acetate+Leuprolide With Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase II Study
ARN-509+Abiraterone Acetate+Leuprolide With Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase II Study
Enrollment Status: Active_not_recruiting
Publish Date: May 20, 2025
Intervention Type: Drug, Radiation
Study Drugs: ARN-509, Abiraterone, Leuprolide
Study Phase: Phase 2
TELEPORT STUDY: A Pilot Feasibility Trial Examining The Use of Telehealth in Post Radiation Therapy Visits
TELEPORT STUDY: A Pilot Feasibility Trial Examining The Use of Telehealth in Post Radiation Therapy Visits
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other
Study Phase: Not Applicable
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Radiation, Drug
Study Drug: MK-3475
Study Phase: Phase 1
A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers
A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Other
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug, Other
Study Drug: 177Lu-PSMA-617
Study Phase: Phase 3
Phase IB/II Study of Enzalutamide With Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression
Phase IB/II Study of Enzalutamide With Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression
Enrollment Status: Completed
Publish Date: May 13, 2024
Intervention Type: Procedure, Other, Drug
Study Drugs: Enzalutamide, Ribociclib
Study Phase: Phase 1/Phase 2
View 12 Less Clinical Trials

177 Total Publications

Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial.
Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial.
Journal: European urology oncology
Published: March 25, 2025
View All 177 Publications
Similar Doctors
Carol L. Shields
Elite in Retinoblastoma
Dr. Carol L. Shields
Ophthalmology | Oncology
Elite in Retinoblastoma
Dr. Carol L. Shields
Ophthalmology | Oncology

Ophthalmology - Wills Eye Hospital

840 Walnut Street, Floor 10, 
Philadelphia, PA 
 (0.2 miles away)
215-928-3105
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Carol Shields is an Oncologist and an Ophthalmologist in Philadelphia, Pennsylvania. Dr. Shields is rated as an Elite provider by MediFind in the treatment of Retinoblastoma. Her top areas of expertise are Retinoblastoma, Melanoma of the Eye, Uveal Melanoma, Vitrectomy, and Iridectomy. Dr. Shields is currently accepting new patients.

Distinguished in Retinoblastoma
Dr. Amish Shah
Pediatrics | Hematology | Oncology
Distinguished in Retinoblastoma
Dr. Amish Shah
Pediatrics | Hematology | Oncology

Childrens Health Care Associates Inc

3401 Civic Ctr Blvd, 
Philadelphia, PA 
 (1.9 miles away)
215-590-1000
Experience:
18+ years
Languages Spoken:
English
See accepted insurances

Amish Shah is a Pediatrics specialist and a Hematologist in Philadelphia, Pennsylvania. Dr. Shah has been practicing medicine for over 18 years and is rated as an Advanced provider by MediFind in the treatment of Retinoblastoma. His top areas of expertise are Retinoblastoma, Neurofibromatosis, Neurofibromatosis Type 1 (NF1), and Hereditary Retinoblastoma.

Adam P. Dicker
Advanced in Retinoblastoma
Dr. Adam P. Dicker
Radiation Oncology | Oncology
Advanced in Retinoblastoma
Dr. Adam P. Dicker
Radiation Oncology | Oncology

Radiation Oncology At Thomas Jefferson University Hospital

111 South 11th Street, Suite G-301, 
Philadelphia, PA 
 (0.1 miles away)
Languages Spoken:
English, Hebrew
See accepted insurances
Accepting New Patients

Adam Dicker is an Oncologist and a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Dicker is rated as a Distinguished provider by MediFind in the treatment of Retinoblastoma. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Gliomatosis Cerebri, Glioblastoma, and Prostatectomy. Dr. Dicker is currently accepting new patients.

VIEW MORE RETINOBLASTOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Den's expertise for a condition
ConditionClose
  • Elite
  • Prostate Cancer
    Dr. Den is
    Elite
    . Learn about Prostate Cancer.
    See more Prostate Cancer experts
  • Distinguished
  • Familial Prostate Cancer
    Dr. Den is
    Distinguished
    . Learn about Familial Prostate Cancer.
    See more Familial Prostate Cancer experts
  • Prostatectomy
    Dr. Den is
    Distinguished
    . Learn about Prostatectomy.
    See more Prostatectomy experts
  • Advanced
  • Muscle Invasive Bladder Cancer
    Dr. Den is
    Advanced
    . Learn about Muscle Invasive Bladder Cancer.
    See more Muscle Invasive Bladder Cancer experts
  • Retinoblastoma
    Dr. Den is
    Advanced
    . Learn about Retinoblastoma.
    See more Retinoblastoma experts
  • Experienced
  • Anal Cancer
    Dr. Den is
    Experienced
    . Learn about Anal Cancer.
    See more Anal Cancer experts
  • Bone Tumor
    Dr. Den is
    Experienced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Endometrial Cancer
    Dr. Den is
    Experienced
    . Learn about Endometrial Cancer.
    See more Endometrial Cancer experts
  • Endometrial Stromal Sarcoma
    Dr. Den is
    Experienced
    . Learn about Endometrial Stromal Sarcoma.
    See more Endometrial Stromal Sarcoma experts
  • Gliomatosis Cerebri
    Dr. Den is
    Experienced
    . Learn about Gliomatosis Cerebri.
    See more Gliomatosis Cerebri experts
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
    Dr. Den is
    Experienced
    . Learn about Head and Neck Squamous Cell Carcinoma (HNSCC).
    See more Head and Neck Squamous Cell Carcinoma (HNSCC) experts
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.